DELRAY BEACH, Fla., May 19, 2005 (PRIMEZONE) -- Hard To Treat Diseases, Incorporated (HTTD) (Pink Sheets:HTDS) announces today that the Company's trial will commence on Wednesday, May 25th, at 9:30 a.m. in courtroom 205C of the U.S. Courthouse in Fort Lauderdale.
You can monitor the trial's status and the Court's calendar by signing onto the website: www.flsd.uscourts.gov and clicking on "Honorable Daniel T. K. Hurley". HTTD's case is Hard to Treat Diseases, Inc. v. Shinn, 04-80010. This trial is open to the public. As the Court's website states, "Suggested start-up dates are advisory only. Due to settlements and other reasons, the Court reserves the right to call cases for trial earlier than the listed date and out of turn."
It has come to the attention of HTTD that unrelated third-party individuals or entities are releasing information about the Company through fax and/or email blasts and that specific individuals and/or shareholders are misrepresenting the Company and its management. The Company is moving ahead with the goals described in our web site's Corporate Overview. The Company urges all investors and potential investors to review the Company's press releases and web site rather than relying on non-Company disseminated information. Our new web site is nearly complete and will be available before June 1st.
Management's intention and goal with this litigation has been to resolve the current dispute in the most efficient and economical manner to provide the maximum benefit to the Company and to HTTD's shareholders.
HTTD's shareholders and investors will be kept informed of all public developments as they occur regarding the above matters. In order to ensure the confidentiality of the Company's business and legal strategies, certain specific information may not be immediately available. Once such information can be revealed, it will be publicly disclosed to all shareholders.
HTTD is currently involved in litigation regarding the rights to Tubercin(r). Additional information and details regarding the litigation can be viewed at our website at: www.htdsotc.com
Cautionary Note Regarding Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard to Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.